Silence Therapeutics (NASDAQ:SLN) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report report published on Friday, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.

Several other research firms have also recently weighed in on SLN. BMO Capital Markets started coverage on Silence Therapeutics in a research report on Wednesday, January 31st. They set an outperform rating and a $67.00 price objective for the company. Chardan Capital restated a buy rating and set a $42.00 price target on shares of Silence Therapeutics in a research note on Friday, May 17th. Finally, Morgan Stanley restated an overweight rating and set a $45.00 price target on shares of Silence Therapeutics in a research note on Monday, April 22nd.

Silence Therapeutics Stock Performance

Shares of SLN stock traded down $0.09 on Friday, reaching $21.91. 43,820 shares of the company’s stock traded hands, compared to its average volume of 132,535. Silence Therapeutics has a 12-month low of $4.84 and a 12-month high of $27.72. The business’s 50 day moving average price is $22.02 and its two-hundred day moving average price is $19.47.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.18. The business had revenue of $15.73 million during the quarter, compared to analyst estimates of $4.53 million. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. On average, sell-side analysts predict that Silence Therapeutics will post -1.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

A number of large investors have recently bought and sold shares of the business. Redmile Group LLC bought a new stake in Silence Therapeutics during the 1st quarter worth approximately $43,798,000. Vivo Capital LLC lifted its holdings in Silence Therapeutics by 116.7% during the 1st quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock worth $23,878,000 after buying an additional 595,250 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Silence Therapeutics during the 1st quarter worth $13,575,000. Lynx1 Capital Management LP acquired a new position in Silence Therapeutics during the 3rd quarter worth $2,315,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in Silence Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after buying an additional 40,063 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.